CNAT Conatus Pharmaceuticals Inc. gains 22% Sep 5, 2018

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. The company was founded in 2005 and is headquartered in San Diego, California.http://www.priceseries.com/trade/CNAT-Conatus-Pharmaceuticals-Inc-stock-gains-22-percent-a-Trade-Record-by-priceSeries-2018082220180905.html